SAMSUNG-ELECTRONICS
24.2.2021 11:02:11 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today announced that it has begun mass producing its most advanced line of data center SSDs, the PM9A3 E1.S.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005429/en/
The new PM9A3 fully complies with the Open Compute Project (OCP) NVMe Cloud SSD Specification to satisfy the rigorous demands of enterprise workloads. Defined by leading data center providers including Facebook, the OCP Specification is a set of unified interoperable standards, enabling SSD vendors to work toward next-generation storage designs with much more effectiveness.
"Wider 5G deployment and accelerating growth in IoT devices are fueling a hyperconnected lifestyle, driving the demand for more sophisticated hyperscale data centers," said Cheolmin Park, vice president of Memory Product Planning at Samsung Electronics. "Providing an optimal mix of performance, power, reliability and firmware, we believe our new PM9A3 will help advance today's data center storage technologies and expand the market for OCP-compliant SSDs."
“Innovations such as the OCP NVMe Cloud SSD and E1.S are important to solving today’s data center challenges. The OCP NVMe Cloud SSD Specification defines hyperscale SSD requirements, enabling SSD makers to provide leading-edge products that meet the challenging demands of hyperscale environments. Deploying storage at scale is very challenging and Samsung’s support for next-generation industry-leading technologies such as the OCP NVMe Cloud SSD and EDSFF E1.S is a great step forward,” said Ross Stenfort, Hardware Storage Engineer at Facebook.
Built with the company's sixth-generation (1xx-layer) V-NAND, the PM9A3 dramatically improves performance over the fifth-generation V-NAND-based PM983a (M.2), with double the sequential write speed at 3000MB/s, a 40% higher random read speed of 750K IOPS and 150% higher random writes at 160K IOPS.
Power features are critical to maximizing the efficiency of data center operations. The PM9A3 provides superior power efficiency at 283MB/s per watt for sequential writes, making it nearly 50% more energy efficient than the previous generation’s 188MB/s per watt. In fact, replacing all server hard disk drives (HDDs) launched in 2020 with the PM9A3 4TB drive would save 1,484 gigawatt hours (GWh) of energy, which is enough electricity to power all households in a major metropolitan city during a summer month*.
The PM9A3 also comes in nine power levels to suit a diverse range of SSD form factors and interfaces — from 8.25 watts for the M.2 form factor to 35W for newer form factors such as EDSFF.
In addition to standard security features such as user data encryption and authentication, the new drive is equipped with secure boot and anti-rollback mechanisms to ensure robust data protection. Secure boot adds another layer of protection against unauthorized firmware being used, while anti-rollback prevents the drive from rolling back or downgrading to an older flawed version of the firmware.
Samsung will continue to work closely with its data center partners to standardize advanced storage technologies, and facilitate the development of more cutting-edge memory solutions.
* Editor’s note: based on a total of 1,412 GWh of electricity consumed by households in Seoul, Korea, during August 2020
###
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005429/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom